A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 208 participants.

Also called NCT05063253

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 208 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05063253
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05063253. Randomized; quadruple masking; primary purpose treatment. Start 2021-10 (anticipated); primary completion 2024-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
TG103
Intervention (Drug)
Placebo
Lead sponsor
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05063253
Content hash
046827267b75f69bd5af680e62a521038f45a4513b4585adc34e270e32df5d29